TibaRay announced that its first Galactica cancer treatment systems have entered manufacturing. The milestone moves the Silicon Valley medical technology company’s next-generation radiotherapy platform closer to clinical deployment.
TibaRay was founded on research from Stanford University. The company’s technology is built on accelerator technology originally invented at Stanford and is designed to represent the first fundamentally new class of medical linear accelerator in nearly 70 years.
The Galactica system generates the high-energy X-rays used to treat cancer in a smaller and more efficient platform. TibaRay said the technology is designed to improve treatment precision while reducing the cost, size, and complexity of advanced radiotherapy equipment.
The system has also been designed for integration into a leading upright radiotherapy platform. This allows patients to receive treatment while sitting or standing rather than lying down, which can improve patient comfort while supporting precise treatment delivery and reducing system size.
Radiotherapy remains a critical part of cancer care, with nearly two-thirds of patients with cancer benefiting from radiation treatment. However, TibaRay noted that many physicians still rely on large and expensive linear accelerators based on technology developed decades ago.
The company said Galactica is intended to help address several long-standing challenges in radiation oncology, including precision, accessibility, patient comfort, and equipment complexity. By moving into manufacturing, TibaRay is advancing from research and engineering development toward real-world clinical installation.
Galactica also forms the foundation for TibaRay’s longer-term vision of enabling FLASH radiotherapy. FLASH is an emerging treatment approach that researchers believe could potentially eliminate tumors while minimizing damage to surrounding healthy tissue by delivering radiation in a fraction of a second.
TibaRay said the manufacturing milestone is part of its broader implementation strategy as it prepares for its first clinical installations. The company is continuing to develop technologies intended to make radiotherapy faster, more precise, and more accessible for cancer patients worldwide.
The systems will be integrated into Leo Cancer Care’s advanced radiotherapy platform. The first installation is planned for later this year at Mayo Clinic.
TibaRay is focused on advancing linear accelerator technology for radiotherapy and other commercial applications. Its platform is designed to help physicians deliver radiotherapy with greater precision, speed, and efficiency while also supporting broader uses of compact, high-performance linear accelerators beyond cancer care.
KEY QUOTES:
“For years, our team has focused on solving radiation oncology’s biggest challenge of making treatment more precise, more accessible and ultimately available to more patients. Moving into manufacturing means Galactica is coming to life. We have reached a major engineering milestone that transforms years of innovation into a technology ready for real-world clinical deployment.”
Thinh Tran, CEO of TibaRay
